HALO
Halozyme Therapeutics, Inc.
Biotechnology · Healthcare · United States
131.18
close · 2026-10-29
value
46
cheaper than peers46
quality
81
stronger fundamentals81
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 12.28× | 76 |
| price to sales | 7.32× | 65 |
| EV to EBITDA | 12.99× | 55 |
| price to book | 104.19× | 2 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 173.7% | 100 |
| operating margin | 59.8% | 98 |
| revenue growth | 47.7% | 65 |
| debt to equity | 1517.7% | 3 |
4 of 4 measures available
Facts
| market cap | $15B |
| free cash flow | $337.3M |
| employees | 423 |
| first trade | 2004-03-16 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 2.56 | 3.43 | 2.10 | 1.44 |
| free cash flow | $356.8M | $468.4M | $373.3M | $235.3M |
| net income | $316.9M | $444.1M | $281.6M | $202.1M |
| revenue | $1.40B | $1.02B | $829.3M | $660.1M |
| unusual items | -$317.6M | $23.8M | $29.5M | -$1.7M |